Fibrinolysis as a Causative Mechanism for Bleeding Complications on Extracorporeal Membrane Oxygenation: A Pilot Observational Prospective Study

被引:12
作者
Helms, Julie [1 ,2 ,3 ,9 ]
Curtiaud, Anais [1 ,2 ,3 ]
Severac, Francois [4 ]
Tschirhart, Marine [3 ]
Merdji, Hamid [1 ,2 ,3 ]
Bourdin, Matthieu [5 ]
Contant, Genevieve [5 ]
Depasse, Francois [6 ]
Abou Rjeily, Ramy [7 ]
Sattler, Laurent [8 ]
Meziani, Ferhat [1 ,2 ,3 ]
Angles-Cano, Eduardo [7 ,10 ]
机构
[1] Strasbourg Univ UNISTRA, Strasbourg, France
[2] Strasbourg Univ Hosp, Med Intens Care Unit NHC, Strasbourg, France
[3] INSERM French Natl Inst Hlth & Med Res, Unit 1260, Regenerat Nanomed, Med Federat Strasbourg, Strasbourg, France
[4] Strasbourg Univ Hosp, Clin Res Methods Grp GMRC, Strasbourg, France
[5] Diagnost Stago, Prospective Res Dept, Gennevilliers, France
[6] Diagnost Stago, Clin Dev, Asnieres, France
[7] Paris Cite Univ, INSERM, U1140, Innovat Therapies Haemostasis, Paris, France
[8] Strasbourg Univ Hosp, Lab Hematol, Strasbourg, France
[9] Nouvel Hop Civil, Serv Med Intens Reanimat, 1 Pl Hop, F-67091 Strasbourg, France
[10] Univ Paris Cite, INSERM, 4 Ave Observ, F-75006 Paris, France
关键词
TISSUE-PLASMINOGEN-ACTIVATOR; SODIUM DODECYL-SULFATE; CARDIOPULMONARY BYPASS; BRADYKININ; INHIBITOR-1; COMPLEXES;
D O I
10.1097/ALN.0000000000004980
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background:Extracorporeal membrane oxygenation (ECMO) is associated with a high risk of bleeding complications. The specific impact of ECMO on fibrinolysis remains unexplored. The objective of the current pilot observational prospective study was to investigate the longitudinal dynamics of fibrinolytic markers-i.e., changes over time-in the context of bleeding events in patients on ECMO.Methods:Longitudinal dynamics of contact phase components (kininogen and bradykinin) and fibrinolysis markers (tissue plasminogen activator [tPA], plasminogen activator inhibitor-1 [PAI-1], their complexes [tPA center dot PAI-1], plasmin-antiplasmin complexes, plasminogen, and D-dimer) were measured in patients undergoing venovenous and venoarterial ECMO, before implantation, at 0, 6, and 12 h after implantation, and daily thereafter.Results:The cohort consisted of 30 patients (214 ECMO days). The concentrations of tPA, D-dimer, plasmin-antiplasmin complexes, PAI-1, and tPA center dot PAI-1 complexes were increased, whereas plasminogen decreased compared to normal values. A noteworthy divergence was observed between hemorrhagic and nonhemorrhagic patients: in bleeding patients, D-dimer, plasmin-antiplasmin, tPA, PAI-1, and tPA center dot PAI-1 followed an increasing kinetics before hemorrhage and then decreased to their baseline level; conversely, nonbleeding patients showed a decreasing kinetics in these markers. Also, D-dimer and tPA followed an increasing kinetics in bleeding patients compared to nonbleeding patients (median values for D-dimer dynamics: 1,080 vs. -440 ng/ml, P = 0.05; tPA dynamics: 0.130 vs. 0.100 nM, P = 0.038), and both markers significantly increased the day before hemorrhage. A tPA concentration above 0.304 nM was associated with bleeding events (odds ratio, 4.92; 95% CI, 1.01 to 24.08; P = 0.049).Conclusions:Contact activation induces fibrinolysis in ECMO patients, especially in patients experiencing bleeding. This finding supports the role of this mechanism as a possible causal factor for hemorrhages during ECMO and open new avenues for novel therapeutic perspectives. In patients requiring cardiac and/or pulmonary support with extracorporeal membrane oxygenation, D-dimer and tissue plasminogen activator levels were increased with bleeding, findings consistent with fibrinolysis. Although there are multiple causes for fibrinolysis during extracorporeal membrane oxygenation, their study suggests that patients who bled had increased contact activation and may benefit from novel therapeutic agents that inhibit hemostatic activation through this pathway.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 45 条
[1]  
[Anonymous], 2017, Extracorporeal Life Support Organization (ELSO) General Guidelines for all ECLS Cases
[2]   Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial [J].
Balaguer, J. M. ;
Yu, C. ;
Byrne, J. G. ;
Ball, S. K. ;
Petracek, M. R. ;
Brown, N. J. ;
Pretorius, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) :326-334
[3]   Managing the coagulopathy associated with cardiopulmonary bypass [J].
Bartoszko, Justyna ;
Karkouti, Keyvan .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (03) :617-632
[4]   An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database [J].
Billingham, Sophie A. M. ;
Whitehead, Amy L. ;
Julious, Steven A. .
BMC MEDICAL RESEARCH METHODOLOGY, 2013, 13
[5]   STATISTICS NOTES .12. CALCULATING CORRELATION-COEFFICIENTS WITH REPEATED OBSERVATIONS .1. CORRELATION WITHIN-SUBJECTS [J].
BLAND, JM ;
ALTMAN, DG .
BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :446-446
[6]  
Brown NJ, 2000, CIRCULATION, V102, P2190
[7]   Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: Four adult case reports and a review of the literature [J].
Buckley, Leo F. ;
Reardon, David P. ;
Camp, Phillip C. ;
Weinhouse, Gerald L. ;
Silver, David A. ;
Couper, Gregory S. ;
Connors, Jean M. .
HEART & LUNG, 2016, 45 (03) :232-236
[8]  
Buckvold SM, 2017, AM J RESP CRIT CARE, V196, P676, DOI 10.1164/rccm.201704-0723ED
[9]   Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans [J].
Campbell, DJ ;
Dixon, B ;
Kladis, A ;
Kemme, M ;
Santamaria, JD .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (04) :R1059-R1070
[10]   Association of D-dimer and Fibrinogen With Hypercoagulability in COVID-19 Requiring Extracorporeal Membrane Oxygenation [J].
Chandel, Abhimanyu ;
Patolia, Saloni ;
Looby, Mary ;
Bade, Najeebah ;
Khangoora, Vikramjit ;
King, Christopher S. .
JOURNAL OF INTENSIVE CARE MEDICINE, 2021, 36 (06) :689-695